Background:
Compared with other insulin regimens, combination therapy with oral hypoglycemic agents and bedtime insulin produces similar improvement in glycemic control but induces less weight gain.
Objective:
To determine whether bedtime insulin regimens differ with respect to their effects on weight gain in patients with type 2 diabetes.
Design:
Randomized, controlled trial.
Setting:
Four outpatient clinics at central hospitals.
Patients:
96 patients (mean age, 58 ± 1 years; mean body mass index, 29 ± 1 kg/m2) whose type 2 diabetes was poorly controlled with sulfonylurea therapy (mean glycosylated hemoglobin value, 9.9% ± 0.2%; mean fasting plasma glucose level, 11.9 ± 0.3 mmol/L [214 ± 5 mg/dL]).
Intervention:
Random assignment to 1 year of treatment with bedtime intermediate-acting insulin plus glyburide (10.5 mg) and placebo, metformin (2 g) and placebo, glyburide and metformin, or a second injection of intermediate-acting insulin in the morning. Patients were taught to adjust the bedtime insulin dose on the basis of fasting glucose measurements.
Measurements:
Body weight, biochemical and symptomatic hypoglycemias, and indices of glycemic control.
Results:
At 1 year, body weight remained unchanged in patients receiving bedtime insulin plus metformin (mean change, 0.9 ± 1.2 kg; P < 0.001 compared with all other groups) but increased by 3.9 ± 0.7 kg, 3.6 ± 1.2 kg, and 4.6 ± 1.0 kg in patients receiving bedtime insulin plus glyburide, those receiving bedtime insulin plus both oral drugs, and those receiving bedtime and morning insulin, respectively. The greatest decrease in the glycosylated hemoglobin value was observed in the bedtime insulin and metformin group (from 9.7% ± 0.4% to 7.2% ± 0.2% [difference, −2.5 ± 0.4 percentage points] at 1 year; P < 0.001 compared with 0 months and P < 0.05 compared with other groups). This group also had significantly fewer symptomatic and biochemical cases of hypoglycemia (P < 0.05) than the other groups.
Conclusions:
Combination therapy with bedtime insulin plus metformin prevents weight gain. This regimen also seems superior to other bedtime insulin regimens with respect to improvement in glycemic control and frequency of hypoglycemia.
References
- 1.
- 2.
- 3.
Pugh JA ,Wagner ML ,Sawyer J ,Ramirez G ,Tuley M ,Friedberg SJ . Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care. 1992;15:953-9. CrossrefMedlineGoogle Scholar - 4.
Peters AL ,Davidson MB . Insulin plus sulfonylurea agent for treating type 2 diabetes. Ann Intern Med. 1991;115:45-53. LinkGoogle Scholar - 5.
Johnson JL ,Wolf SL ,Kabadi UM . Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156:259-64. CrossrefMedlineGoogle Scholar - 6.
Yki-Järvinen H ,Kauppila M ,Kujansuu E ,Lahti J ,Marjanen T ,Niskanen L ,et al . Comparison of insulin regimens in patients with non–insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-33. CrossrefMedlineGoogle Scholar - 7.
Yki-Järvinen H ,Ryysy L ,Kauppila M ,Kujansuu E ,Lahti J ,Marjanen T ,et al . Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:4037-43. CrossrefMedlineGoogle Scholar - 8.
Saudek CD ,Duckworth WC ,Giobbie-Hurder A ,Henderson WG ,Henry RR ,Kelley DE ,et al . Implantable insulin pump vs multiple-dose insulin for non–insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA. 1996;276:1322-7. CrossrefMedlineGoogle Scholar - 9.
Taves DR . Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974;15:443-53. CrossrefMedlineGoogle Scholar - 10.
Lapidus L ,Bengtson C ,Larsson B ,Pennert K ,Rybo E ,Sjöström L . Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J Clin Res Ed. 1984;289:1257-61. CrossrefMedlineGoogle Scholar - 11.
Desbuquois B ,Aurbach GD . Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab. 1971;33:732-8. CrossrefMedlineGoogle Scholar - 12. Gidez LJ, Miller GJ, Burstein M, Eder HA. Analysis of plasma high density lipoprotein subclasses by a precipitation procedure: correlation with preparative and analytical ultracentrifugation. In: Lippel K, ed. Report of the High Density Lipoprotein Methodology Workshop. Bethesda, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health; 1998:328-40. NIH publication no. 79-661. Google Scholar
- 13.
Bruce DG ,Clark EM ,Campbell LV ,Chisholm DJ . Insulin therapy in patients with poorly controlled non–insulin-dependent diabetes mellitus. Med J Aust. 1987;146:240-2. CrossrefMedlineGoogle Scholar - 14.
DeFronzo RA ,Goodman AM . Efficacy of metformin in patients with non–insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-9. CrossrefMedlineGoogle Scholar - 15.
- 16.
Gutniak M ,Karlander SG ,Efendic S . Glyburide decreases insulin requirement, increases β-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care. 1987;10:545-54. CrossrefMedlineGoogle Scholar - 17.
Quatraro A ,Consoli G ,Ceriello A ,Giugliano D . Combined insulin and sulfonylurea therapy in non–insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab. 1986;12:315-8. MedlineGoogle Scholar - 18.
Abraira C ,Colwell JA ,Nuttall FQ ,Sawin CT ,Nagel NJ ,Comstock JP ,et al . Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113-23. CrossrefMedlineGoogle Scholar - 19.
- 20. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with non–insulin-dependent diabetes mellitus. Diabetologia. [In press]. Google Scholar
- 21.
Author, Article, and Disclosure Information
From University of Helsinki, Helsinki; Kymenlaakso Central Hospital, Kotka; Jorvi Hospital and Orion, Espoo; Lapland Central Hospital, Rovaniemi; and South Carelian Central Hospital, Lappeenranta, Finland.
Grant Support: By the Academy of Finland (Dr. Yki-Järvinen). Antidiabetic drugs, including placebo tablets, were prepared by Orion, Espoo, Finland.
Acknowledgments: The authors thank nurses Liisa Hyvärinen, Raija Härkönen, Leena Pekkonen, and Mare Riihelä for their help, patience, and educational skills. They also thank Kikka Runeberg, Sari Hämäläinen, and Kati Tuomola for technical assistance.
Corresponding Author: Hannele Yki-Järvinen, MD, Department of Medicine, University of Helsinki, Haartmaninkatu 4, Box 340, FIN-00029 HUCH, Helsinki, Finland.
Current Author Addresses: Dr. Yki-Järvinen: Department of Medicine, University of Helsinki, Haartmaninkatu 4, Box 340, FIN-00029 HUCH, Helsinki, Finland.
Dr. Ryysy: Kymenlaakso Central Hospital, FIN-48210 Kotka, Finland.
Dr. Nikkilä: Jorvi Hospital, Turuntie 150, FIN-02740 Espoo, Finland.
Dr. Tulokas: Lapland Central Hospital, Box 8041, FIN-96101 Rovaniemi, Finland.
Dr. Vanamo: South Carelian Central Hospital, Valto Käkelän katu, FIN-53130 Lappeenranta, Finland.
Ms. Heikkilä: Orion, Box 65, FIN-02101 Espoo, Finland.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.